• 1
    Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117: 5463.
  • 2
    Sugarbaker DJ, Jaklitsch MT, Bueno R et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004; 128: 13846.
  • 3
    Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 263644.
  • 4
    Robinson BW, Creaney J, Lake R et al. Soluble mesothelin-related protein − a blood test for mesothelioma. Lung Cancer 2005; 49: 10911.
  • 5
    Robinson BW, Creaney J, Lake R et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 161216.
  • 6
    Hino O, Kobayashi E, Nishizawa M et al. Renal carcinogenesis in the Eker rat. J Cancer Res Clin Oncol 1995; 121: 6025.
  • 7
    Yamashita Y, Yokoyama M, Kobayashi E, Takai S, Hino O. Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem Biophys Res Commun 2000; 275: 13440.
  • 8
    Hino O. Multistep renal carcinogenesis in the Eker (Tsc 2 gene mutant) rat model. Curr Mol Med 2004; 4: 80711.
  • 9
    Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004; 10: 393742.
  • 10
    Hassan R, Remaley AT, Sampson ML et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006; 12: 44753.
  • 11
    Pass HI, Lott D, Lonardo F et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353: 156473.